If you’ve been following alternative energy ETFs, you know they’re down – many are between 25% and 40% below where they traded a year ago.
And their downfall isn’t only from higher interest rates: the S&P SPDR Biotech ETF (NYSE: XBI) contains early-stage stocks whose profit forecasts share some common ground with early-stage energy companies, and which also got a beat-down as rates rose – yet this biotech ETF is up nearly 12% over the past year.
Simon Erickson, founder of stock research service 7investing.com (and former alternative energy analyst), joins BBAE CIO James Early to explain what’s going on, why he doesn’t like clean energy ETFs, and why he does like Wolfspeed (NYSE: WOLF) as a quasi-energy alternative to (no pun intended) pure-play alternative energy.
James
This article is for informational purposes only and is neither investment advice nor a solicitation to buy or sell securities. All investment involves inherent risks, including the total loss of principal, and past performance is not a guarantee of future results. Always conduct thorough research or consult with a financial expert before making any investment decisions. James owns shares of XBI. BBAE has no position in any investment mentioned.
